SAN DIEGO--(BUSINESS WIRE)--Epic Sciences, Inc. (“Epic” or “Epic Sciences”), a privately held diagnostics company, has completed a $24 million Series G which together with its $43 million Series F financing, totals $67 million raised in the last twelve months. The company will use the capital from this additional round of private investment to fund the commercial infrastructure required to commercialize the three component tests of DefineMBC, which together provide a comprehensive blood-based biopsy result for patients with metastatic breast cancer.
The investment was co-led by Deerfield Management and Arsenal Capital Partners, and included broad participation from the company’s shareholders including Blue Ox Healthcare Partners, Domain Ventures, and Labcorp.
“I’m excited to announce that Epic’s pre-launch activities related to DefineMBC have exceeded our expectations. We have delivered comprehensive test results to 700 patients and their oncologists in our Clinical Experience Program,” said Lloyd Sanders, President and CEO, Epic Sciences. “We have surveyed the physicians participating in the Clinical Experience Program and their responses indicate that oncologists see the value in DefineMBC’s ability to provide actionable information that allows them to better care for their patients.”
DefineMBC™ provides the most comprehensive blood-based biopsy results available to patients with metastatic breast cancer by delivering a report which includes:
- detection of circulating tumor cells (CTCs)
-
assessment of HER-2 cellular protein expression coupled with
- single-cell sequencing of identified cells to assess amplification of the ERBB2 gene locus
- assessment of ER cellular protein expression
-
a plasma-based, 56-gene panel of cell-free DNA including
- ERBB2 and PIK3CA
- tumor mutational burden (TMB)
The new investment will enable the company’s efforts related to the commercialization of the DefineMBC tests, including the continued expansion of the company’s new market-facing departments: sales, product marketing, customer service, medical affairs, payer markets, and billing. The investment also continues to fund the development of additional concordance and outcomes data for the DefineMBC tests.
Andrew El Bardissi, a member of the company’s board of directors and Partner at Deerfield Management, said, “Deerfield is pleased to support Epic Sciences at this critical stage of commercialization. We believe DefineMBC is poised to change the management of metastatic breast cancer.”
About Epic Sciences
Epic Sciences, Inc. is developing and marketing novel diagnostics to guide therapy selection and monitor disease progression, personalizing and advancing the treatment and management of prostate and breast cancers. The company’s liquid biopsy platform leverages proven, proprietary cell analysis capabilities as well as cell-free analysis to provide more complete, efficient analysis and clearer insights – Comprehensive Cancer Profiling. Using its full-service CAP/CLIA-accredited laboratory and research support services, Epic Sciences partners with leading pharmaceutical companies and major cancer centers around the world to improve patient outcomes.
For more information, visit www.epicsciences.com or follow us on LinkedIn, Facebook or Twitter.
About Arsenal Capital Partners
Arsenal is a leading private equity firm that specializes in investments in healthcare and industrial growth companies. Since its inception in 2000, Arsenal has raised institutional equity investment funds of more than $10 billion, has completed more than 250 platform and add-on investments, and achieved more than 30 realizations. Arsenal invests in industry sectors in which the firm has significant prior knowledge and experience. The firm works with management teams to build strategically important companies with leading market positions, high growth, and high value-add. Visit www.arsenalcapital.com for more information.
